Trial Profile
A Phase II Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 19 Jan 2018 Status changed from active, no longer recruiting to completed.
- 25 Jan 2017 Planned End Date changed from 1 Jul 2015 to 1 Jan 2018.
- 09 Aug 2016 Status changed from recruiting to active, no longer recruiting.